Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors
Retrieved on:
Wednesday, October 18, 2023
Storm, Biomedical Advanced Research and Development Authority, Global health, United States Army Nurse Corps, Certification, Civilization, Defense Advanced GPS Receiver, United States Army War College, Medicine, Kosovo Force, Combat support hospital, RN, Commanding officer, Health, Development, American Public University System, Disease, BioBridge Global, RET, University of Kansas, USAMRIID, University, Fort Detrick, National security, Pandemic, United States Army Medical Research and Development Command, ROTC, Infection, Texas Desert Shield-Desert Storm Campaign Medal, BSN, MSN, Scientific Committee on Oceanic Research, Operation New Dawn, 67th Combat Support Hospital (United States), Nursing, Operation, DARPA
Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.
Key Points:
- Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.
- This appointment adds one of the world's top national security and biodefense research and logistics executives to Maxwell's board.
- "I am pleased to welcome General Holcomb's leadership in national security and patient care to Maxwell's board as we approach human trials next year," said Maxwell Biosciences Chairman and CEO Joshua McClure.
- "General Holcomb is a highly patient-focused medical professional with decades of deep respect within the global and national security biodefense communities.